63% Growth Masks a ₹14 Crore Cash Burn

Highness reported stunning headline numbers: ₹12.01 crore revenue (+63.4% YoY), ₹2.47 crore PAT (+168% YoY), and operating margins that surged from 24.1% to 32.1%. But the operating cash flow crashed to ₹-14.58 crore — a ₹17 crore swing from reported profit. The culprit is not creative accounting; it is brute working capital strain. Trade receivables balloon to ₹13.73 crore (up ₹3.37 crore), and half of the cash from two major customers (UAE and Australia) remains uncollected. This is the quarter the market sees profits; this is the quarter the CFO sees cash burn.

Revenue growth of 63.4% is genuine: ₹12.01 crore vs. ₹7.35 crore prior year, driven by order execution across defense, aerospace, railways, medical, and metro segments. The surprise is the margin: operating EBITDA expanded to 32.1% from 24.1%, and PAT margin to 20.6% from 12.5%. The driver is operational leverage. COGS rose to ₹2.7 crore from ₹2.26 crore (a 19.5% absolute increase), while revenue grew 63.4%. More tellingly, COGS as a percentage of revenue fell from 30.7% to 22.5%—an 8.2 percentage-point expansion. On the surface, this looks like operational excellence and mix shift. Below the surface, it is almost certainly unsustainable.

The story is working capital, not profitability. Receivables from two majors (UAE and Australia) are stuck at 50% of prior-year collections due to mechanical issues and extended payment terms negotiated on-call. Management says the remaining 50% is coming in tranches by October, but the timing mismatch is severe. Additionally, supplier advances paid upfront and other working-capital items consumed cash. The result: positive accounting profit, negative operational cash. This is the squeeze that matters for a company about to spend ₹21 crore on the Goa facility capex.

COGS leverage is supported in H1 but unsustainably low; margin compression likely in H2 as the base normalizes and competitive pressure sets in. Receivables management is supported in substance (collections are happening) but partial on timing — the 50% pending is a material drag and customer concentration risk. The ₹30 crore order book is supported but heavily skewed toward two customers (PLI-obligated second customer and energy sector MOU, both at advanced stage). Medical displays and metros are genuine catalysts; management has design wins and field-proven pilots (1000+ units in Dubai Metro). Goa facility is on track administratively, but the 9-month timeline is weather-dependent and contingent on no approval delays. Management is not overstating, but the confidence on execution is reasonable, not certain.

Four upgrades and one downgrade crystallized on the call:

The stock is at ₹331.3, its all-time high, posting a 109% gain off the 52-week low of ₹158.5. The trend is bullish, but the RSI is overbought at 74.6, a warning of excessive enthusiasm. Volume is normal, so the rally is not thin-air. Ownership has shifted sharply: FII holdings jumped from 0.00% to 5.35% and DII from 0.00% to 10.62% in a single quarter, while promoters trimmed from 95.56% to 64.96%. This is a classic institutional rotation at work: FII/DII are buying the growth story aggressively, but promoters are taking chips off the table at highs. The divergence is telling. Promoters' actions speak louder than calls; they are distributing into the rally. Whether the institutions have the right call (strong catalysts offset the cash burn) or the promoters are right (valuations don't reflect execution risk) will be resolved in H2 FY27 and Q4.